Hospital Ruber Internacional
Mutation testing for KRAS, NRAS, and BRAF in Spain typically costs from $600 to $1,200. The final price depends on the molecular technique used and the clinic location. Patients save about 45% compared to the US, where similar genetic testing averages $1,100. Most clinics in Madrid and Barcelona offer results within several business days.
Bookimed Expert Insight: Choosing a facility with integrated research units can significantly impact the speed of results. Hospital Universitario HM Sanchinarro features a liquid biopsy program for molecular tumor analysis. This allows for genetic profiling without the need for invasive surgery. Dr. Antonio Cubillo Gracián leads these efforts using specific molecular markers for targeted cancer care. SJD Barcelona Children’s Hospital also operates a dedicated Laboratory for Molecular Medicine for innovation. These specialized hubs treat thousands of international patients annually with high-rated JCI-accredited standards.
| Turkey | Austria | Spain | |
| KRAS, NRAS,BRAF mutation testing | from $150 | from $750 | from $550 |
No hidden fees – just official clinic prices. Pay at the clinic for KRAS, NRAS,BRAF mutation testing upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in KRAS, NRAS,BRAF mutation testing and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your KRAS, NRAS,BRAF mutation testing journey.
Dr. Agusti Barnadas Molins is the chief breast cancer specialist at Teknon Oncology Institute in Barcelona. He has directed more than 70 research projects on breast cancer and gynecological oncology. Dr. Barnadas Molins treats tumors using chemotherapy, gland therapy, and immunotherapy. He practices at JCI-accredited Centro Médico Teknon.
Dr. Antonio Cubillo Gracián pioneered the first liquid biopsy program in Spain. He uses genetic data to guide KRAS, NRAS, and BRAF mutation testing for targeted therapy.